Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Efficacy of Zasocitinib (TAK-279), a Selective Oral TYK2 Inhibitor, in Achieving Skin Clearance in Moderate-to-Severe Plaque Psoriasis: Insights from Post Hoc Analyses of a Phase IIb Randomized Trial

  • By

  • Nada Elbuluk

  • April W. Armstrong

  • Ronald Vender

  • Tina Bhutani

  • Lawrence Green

  • Laura K. Ferris

  • Vivian Laquer

  • Angela Moore

  • Jamie Weisman

  • Wenwen Zhang

  • Warren Winkelman

  • Melinda J. Gooderham

  • May 16, 2026

Share

Original Source(s)

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial

  • by Nada Elbuluk, April W. Armstrong, Ronald Vender, Tina Bhutani, Lawrence Green, Laura K. Ferris, Vivian Laquer, Angela Moore, Jamie Weisman, Wenwen Zhang, Warren Winkelman, Melinda J. Gooderham

  • May 16, 2026

Related Content

Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face”

Understanding Social Drivers of Health Among US Adults with Psoriasis from Different Races and Ethnicities

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.